

OPP Session Number	OPP Session Title:	Presentation Date:	Session Time:	Room:	OPP Leaders	Number	Title	Presentation Order:
OPP 01	Parkinson's Disease: Clinical Trials	Monday, October 6	12:30-13:30	312	Tiago Mestre and Tatyana Simuni	940	Safety, Tolerability, and Preliminary Efficacy of NouvNeu001 for the Treatment of Advanced Parkinson's Disease: A Multi-center, Open Label, Phase 1 Study	1
						941	Long-Term Effect of Opicapone in Parkinson's Patients Without Motor Complications: 1.5-year EPSILON Study Findings	2
						942	Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson's Disease (PD)	3
						943	PADOVA: Topline results from a Phase IIb study of prasinezumab in early-stage Parkinson's disease participants on stable symptomatic treatment	4
						944	Continued Evaluation of Bemdaneprocel Following a Phase 1 Study for Parkinson's Disease: Outcomes Through 3 Years	5
						945	Impact of Allogeneic Mesenchymal Stem Cells in Motor and Non-Motor Symptoms of Parkinson's Disease: A Phase 2 Randomized Trial	6
						946	Peripheral insulin resistance may predict exenatide treatment response in Parkinson's disease	7
						947	Trans-Spinal Theta Burst Magnetic Stimulation Enhances Treadmill Training Effects on Gait in Parkinson's Disease	8
						948	LRRK2 antisense oligonucleotide (BIIB094/ON859) impact on cerebrospinal fluid biomarkers in Parkinson's disease patients	9
OPP 02	Parkinson's Disease: Genetics	Monday, October 6	12:30-13:30	315	Niccolo Mencacci	1626	Exome-wide Burden Analysis Identifies SYT10 as a Genetic Modifier of GBA-PD in UK Biobank	1
						1627	Impact of rare lysosomal gene variants on Parkinson's disease	2
						1628	A Pan-Indian Genome-Wide Association Study of Parkinson's Disease	3
						1629	Applying growth mixture models to elucidate heterogeneous trajectories of cognitive change in Parkinson's Disease	4
						1630	The Role of Polygenic Background and APOE E4 in Monogenic and Idiopathic Parkinson's Disease	5
						1631	Screening for GBA1 p.K198E PD-Risk Variant in Latin America	6
						LBA 1	Largest genotype-phenotype association study in Latin American cohorts highlights the role of ITPKB in PD risk	7
OPP 03	Parkinson's Disease: Surgical Therapy and Other	Monday, October 6	12:30-13:30	313A	K. Ray Chaudhuri and Elena Moro	835	A Novel Therapeutic Targeting the tPA-NMDAR Interaction for Parkinson's Disease	1
						836	Lewy Pathology in the Peripheral Nervous System of SNCA Duplication	2
						837	Frequency and outcome of PEG tube implantations in hospitalized Parkinson's disease patients	3
						838	Impact of Cognition on Social Engagement in Community-based Older Adults with Parkinsonism	4
						839	Cerebrospinal fluid DOPA decarboxylase levels as a marker of disease severity in Parkinson's Disease	5
						840	Caregiver Burden after DBS at GPI or STN for Parkinson's Disease	6
						841	Parkinson's Disease Health Policy in 7 African Countries: Results of a Transforming Parkinson's Care in Africa (TraPCAf) Review	7
						1706	Does 10-year STN-DBS impact the natural progression of Parkinsons Disease? A Multicenter Retrospective Controlled Observational Study	8
						1707	Evoked Resonant Neural Activity localises STN DBS programs more ventrally than clinician and imaging-guided methods in Parkinson's disease	9
						1708	Predicting Long Term Outcome of Gait Kinematics with Chronic Deep Brain Stimulation in Patients with Parkinson's Disease	10
OPP 04	AI, Technology, Telemedicine	Monday, October 6	12:30-13:30	314	Roongroj Bhidayasiri and Andrea Pilotto	35	Detection of Early Stage Parkinson's Disease Using Convolutional Neural Network Models and Wearable Sensors from the Six Minute Walk Test	1
						37	Machine Learning Model using Eye Movements for the Differential Diagnosis of iPD and Atypical Parkinsonian Syndromes	2
						38	Joint Prediction of Motor and Non-motor Deep Brain Stimulation Outcomes using Quantitative Susceptibility Mapping	3
						39	Exploring Deep Learning-Based Facial Analysis for Detecting Parkinsonism	4
						40	Machine Learning Analysis of DTI-Derived Free Water Reveals Distinct Parkinson's Disease Subtypes: A Two-Year Longitudinal Study	5
						41	From Explainable AI to Biomarkers: Identifying Disease-Related Brain Regions in Spinocerebellar Ataxia Type 3	6
						42	Quantifying Bradykinesia in Real-world Practice: A Clinician-friendly Video Analysis Tool for Parkinson's Disease	7
						43	Wearable-based Virtual Motor Exam enables remote tracking of motor symptom progression in early-stage Parkinson's disease	8
						86	"PICS": a Novel Radiological Landmark for Thalamic DBS Interventions	9
OPP 05	Pediatric Movement Disorders and Rare Neurometabolic Diseases	Tuesday, October 7	12:30-13:30	314	Lucinda Carr and Emmanuel Roze	LBA 2	Interpretable deep learning framework for PSG-based classification of REM sleep behavior disorder and Parkinson's disease	10
						279	Antisense Oligonucleotide Treatment in Ataxia-Telangiectasia	1
						280	Efficacy and Safety of Ecopipam for Tourette Syndrome (TS): Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Withdrawal Trial	2
						296	Oligodendrocyte-specific mRNA therapy with lipid nanoparticles	3
						297	Precision Gene Therapy Results in Clinical Benefit and Developmental Gains for Aromatic L-Amino Acid Decarboxylase Deficiency (AADCD): The UK Experience	4
						298	Phenotypic Spectrum In Children And Adolescents With Glucose Transporter 1 Deficiency A Multicentric Retrospective Study	5
						299	Genotype-Phenotype Relations in Neurodegeneration with Brain Iron Accumulation (NBIA) Genes: MDSGene Systematic Review	6
						LBA 3	Long-Term Efficacy and Safety of Omaveloxolone in Patients With Friedreich Ataxia: 4-Year Data From the Ongoing MOXIe Open-Label Extension	7
OPP 06	Dystonia	Tuesday, October 7	12:30-13:30	313A	Daniel Corp	LBA 4	N-acetyl-L-leucine: Findings from the Extension Phase of a Phase II Clinical Trial in Ataxia-Telangiectasia	8
						584	The Vodka Trial: Clinical and Genetic Characteristics of Alcohol Responsiveness in Laryngeal Dystonia	1
						555	The Role of the Immune System in Dystonia: Insights from HLA genotyping	2
						556	Biallelic Variants in ACER3 Encoding Alkaline Ceramidase 3 Cause Infantile- and Early-Childhood-Onset Neurodegeneration with Progressive Leukodystrophy	3
						620	Status Dystonicus is a Distinct State Characterized by Pallidal Beta-band Activity	4
						585	Axis Characteristics of Oscillatory Head Movements in Cervical Dystonia	5
						586	Speech and Swallowing Function Following Deep Brain Stimulation for Dystonia?	6
						342	Physiotherapy for Dystonia in the UK: Current Practice, Patient Perspectives, and Future Directions	7

OPP Session Number	OPP Session Title:	Presentation Date:	Session Time:	Room:	OPP Leaders	Number	Title	Presentation Order:
OPP 07	Parkinson's Disease: Biomarkers (non-neuroimaging), Cognition / Psychiatric Manifestations / Lewy Body Dementia, Disease mechanisms, and Etiology (non-genetics)	Tuesday, October 7	12:30-13:30	312	Caroline Williams-Gray	974	The A53T mutation in alpha-synuclein impairs astrocytic metabolism and inflammatory response	1
						975	Clinical Progression and Genetic Pathways in Body-First and Brain-First Par-kinson's Disease	2
						1171	Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body	3
						1172	Interpretable voice-based detection of Parkinson's disease using language-independent graph neural networks	4
						1257	CSF Biomarker-based Cognitive Trajectories in Parkinson's Disease-Subjective Cognitive Decline	5
						1786	Prevalence of Transcobalamin Receptor Antibodies and Relationships with Vitamin B12 and Holotranscobalamin in Parkinson's Disease	6
						977	Alpha-Synuclein Aggregates in the Olfactory Epithelium of Subjects with Parkinson Disease, Dementia, COVID-19, and in Aged Controls	7
						978	Patient-derived α -synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson's disease and Lewy Body Dementia therapeutics	8
OPP 08	Parkinson's Disease: Neuroimaging and Pathophysiology / molecular mechanisms of disease	Tuesday, October 7	12:30 - 13:30	315	Thilo Van Eimeren	LBA 5	Blood extracellular vesicles-based alpha-synuclein biomarker for predicting synucleinopathy clinical symptoms, CSF α -synuclein seeding assay, and postmortem positivity.	9
						LBA 11	Protein signatures in Parkinson's disease and atypical Parkinsonisms	10
						1492	Spatial Multi-Omics Identifies Early Synaptic Pruning and Context-Specific Dopaminergic Vulnerability in Synucleinopathies	1
						1493	Characterising Peripheral Innate Immune Cell Infiltration into the Brain in Parkinson's Disease	2
						1539	Cholinergic activity associates with cognitive function in PD using [18F]VAT	3
						1540	Identifying Cut-off Values, Effects of AD Co-pathology, Sex Differences, and Temporal Changes of 123I-FP-CIT SPECT in Autopsy-proven LBD	4
						1541	Diffusion MRI Changes Linked to α -Synuclein Seed Amplification Status in Parkinson's Disease	5
						1543	Understanding the relationship between synaptic density and dopamine transporter availability in Parkinson's disease	6
OPP 09	Hyperkinetic Movement Disorders (Non-Dystonia)	Wednesday, October 8	12:00 -13:00	315	Francesca Magrinelli	LBA 6	In Situ Detection of α -Synuclein Seeding Activity in Frozen Brain Sections	7
						397	The FGF14-SCA27B GAA•TTC Repeat Shows Marked Somatic Expansion in the Cerebellum	1
						398	Global Genetic Ataxia Resource: An MDSGene Online Platform	2
						399	Long-Term Effectiveness and Tolerability of Vatiquinone in an Adult Friedreich's Ataxia Population	3
						536	A Standardised, Semi-automated Computational Approach to the Analysis of Electrophysiology in Orthostatic Myoclonus	4
						537	MDS Task Force on Tic Disorders: Development of a New Classification Scheme for Tic Disorders	5
						516	Unraveling NKX2-1-related disorders: clinical, genetic, and neuroimaging insights from a global cohort	6
						LBA 7	Vatiquinone Prevents Ferroptosis in Preclinical Models of Friedreich's Ataxia	7
OPP10	Allied Healthcare, Quality of Life, Palliative Care, Patient Perspectives	Wednesday, October 8	12:00 - 13:00	314	Alice Nieuwboer and Elina Tripoliti	LBA 8	Results From the ELATE Trial: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of OnabotulinumtoxinA for the Treatment of Upper Limb Essential Tremor	8
						LBA 9	Mechanism of Action, Preclinical Efficacy, and Safety Evaluation of SAN711/ACP-711, a Novel GABA _A Subunit α_3 Selective Modulator	9
						320	Effectiveness of Intensive Speech Treatment for Friedreich's Ataxia	1
						321	Quantitative evaluation of speech characteristics in Assessment of Motor Speech for Dysarthria (AMSD) using acoustic analysis	2
						340	The Burden of Spasticity in Adults with Cerebral Palsy in South Africa	3
						341	A Multidomain Fall Prevention Program: Perspectives of People with Parkinson's Disease and their Care Partners	4
						332	Developing a Framework for Huntington's Disease Care Partner Training and Support – HD Care Partner Bootcamp Series	5
						190	Cutaneous Phosphorylated Alpha-Synuclein Deposition in Multiple System Atrophy	1
OPP 11	Atypical and Other Parkinsonisms	Wednesday, October 8	12:00 - 13:00	313 A	Hironobu Endo and Edwin Jabbari	250	Safety, Tolerability and Pharmacokinetics of a Novel Oral OGA Inhibitor (FNP-223) First-in-Human Phase 1 Study	2
						251	Brain Target Engagement and Pharmacokinetic-Enzyme Occupancy (PK-EO) Relationship of FNP-223: A Novel Oral OGA Inhibitor for Progressive Supranuclear Palsy - Phase 1 PET Study	3
						252	ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy	4
						196	A rapidly progressive multiple system atrophy-cerebellar variant model presenting α -synuclein oligomer spreading and phosphorylated α -synuclein aggregate formation accompanied with glial inflammation	5
						149	The Genetic and Phenotypic Spectrum of Primary Familial Brain Calcification in a large cohort from China	6
						191	4R-TAU seed amplification assay discriminates tauopathies from non-tauopathies and CBD from PSP in post-mortem brain samples	7
						172	PET and Clinical Evidence for Neuroprotective Effects of KM-819 on MSA	8
						LBA 10	A Multimodal Strategy Integrating Skin α -Synuclein and 4R-Tau SAAs with Circulating NFL to Support the Clinical Diagnosis of Parkinsonian Syndromes	9
OPP12	LBA: Clinical Trials	Wednesday, October 8	12:00 - 13:00	312	Joaquim Ferreira and Joseph Jankovic	LBA 12	Safety, tolerability, pharmacokinetics and pharmacodynamics of VTx3232, a CNS-penetrant NLRP3 inhibitor, in participants with early-stage Parkinson's disease	1
						LBA 13	Phase 1/2a clinical trial of hESC-derived dopaminergic progenitors in Parkinson's disease	2
						LBA 14	First-in-Human Study of Autologous iPSC-Derived Midbrain Dopaminergic Progenitors (UX-DA001) in Parkinson's Disease	3
						LBA 15	Real-World Safety and Effectiveness of Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results	4
						LBA 16	Intracerebroventricular administration of anaerobic dopamine in Parkinson's disease patients with L-dopa-related complications	5
						LBA 17	TEMPO-4: A Phase 3 Open-Label Trial to Investigate the Safety and Efficacy of Long-term Administration of Tavapadon in People With Parkinson's Disease	6
						LBA 19	Longitudinal Changes in Motor, Cognitive, and Functional Outcomes in REM Sleep Behavior Disorder and the Predicted Sample Sizes for Future Clinical Trials	7
						LBA 20	Glovadalen, a D1 Receptor Positive Allosteric Modulator for People With Parkinson's Who Experience Significant Daily Motor Fluctuations: A Phase II, Double-Blind, Randomized Trial	8
						LBA 22	First Clinical Trials of ARV-102, a PROTAC LRRK2 Degradar: Characterization of Pathway Engagement in Healthy Volunteers and Patients With Parkinson's Disease	9